1. Scrip
  2. >>Business

Idorsia’s Quviviq Needs To Rise And Shine After Slow Launch

US Coverage Negotiations And Celebrity DTC Will Be Significant

 
• By Andrew McConaghie

The company’s Quviviq launch has fallen short of early expectations, but Idorsia believes a patient approach will pay off for the blockbuster-tipped insomnia treatment.

Idorsia building 6
Quviviq is Idorsia's first ever commercial product, which it hopes will lead it into profitability by 2025. • Source: Idorsia

Idorsia's newly launched insomnia drug Quviviq has experienced a sluggish start in its first few weeks on the US market with sales well below expectations, but the company remains confident about its long-term future.

The drug recorded revenues of just CHF400,000 (just over $414,000) in Q2 following its launch in early May, far

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.